Bringing hope through science
Journey of innovation
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions.
Read more
Released
Annual Report 2020
“The past year was a transformational year for Oncopeptides highlighted by the FDA´s priority review of our NDA submission, which paved the way for an accelerated approval in the U.S. in early 2021.”
Marty J Duvall, CEO
Click here to watch the film where CEO Marty J Duvall summarizes a transformational year.
Annual Report 2020 - online version
For further information, please contact:
Linda Holmström
Director of Investor Relations
linda.holmstrom@oncopeptides.com
+46 70 873 40 95
Press release -
Oncopeptides presents new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting
Read press release
Upcoming events
-
08:00 CET
-
-
-
-
-
Vision of Oncopeptides
“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
Seminar at the Embassy of Sweden Washington DC
The Embassy of Sweden in Washington DC, Oncopeptides AB, Dana Farber and Uppsala University hosted a virtual seminar on February 2nd,“A Swedish American Journey of Cancer Research”.
Cultures & Values
We are science and data driven, innovative and curious, making decisions based on systematic and thorough analyses.